UK Nuclear Medicine Market Size & Outlook, 2023-2030
UK nuclear medicine market, 2018-2030 (US$M)
Related Markets
UK nuclear medicine market highlights
- The UK nuclear medicine market generated a revenue of USD 395.1 million in 2023 and is expected to reach USD 904.7 million by 2030.
- The UK market is expected to grow at a CAGR of 12.6% from 2024 to 2030.
- In terms of segment, diagnostics was the largest revenue generating product in 2023.
- Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2023 | USD 395.1 million |
| Market revenue in 2030 | USD 904.7 million |
| Growth rate | 12.6% (CAGR from 2023 to 2030) |
| Largest segment | Diagnostics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, UK accounted for 3.9% of the global nuclear medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany nuclear medicine market is projected to lead the regional market in terms of revenue in 2030.
- Netherlands is the fastest growing regional market in Europe and is projected to reach USD 279.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK nuclear medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 73.07% in 2023. Horizon Databook has segmented the UK nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The UK participates in the global Mo-99/Tc-99m supply chain as a generator, manufacturer, and end user of 99mTc in nuclear medicine procedures. In the UK, healthcare funding (even for radioisotope reimbursement) is managed through local Health Trusts.
In addition, increasing adoption of new and advanced technologies by hospitals or regional procurement hubs to provide better treatment to cancer and heart patients is expected to further propel market growth in this country.
Furthermore, local companies are entering into partnerships and collaborations with foreign companies to increase the supply of radioisotopes. For instance, in May 2017, ARTMS Products, Inc. partnered with Alliance Medical to enable and demonstrate non-reactor supply of Tc99m as an alternative.
Reasons to subscribe to UK nuclear medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK nuclear medicine market databook
-
Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into UK nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK nuclear medicine market size, by product, 2018-2030 (US$M)
UK Nuclear Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
